Europe
The trial is still ongoing, but met its primary endpoint of ASAS40.
Key Opinion Leaders in the field of Proton Therapy shared their latest insights and research on FLASH1 irradiation during IBA’s 3rd Victoria Consortium Meeting and IBA’s symposium on Proton Therapy
MorphoSys AG announced that its licensee Janssen Research & Development, LLC issued a press release to report the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration seeking approval of Tremfya for the treatment of adult patients with active psoriatic arthritis.
A study carried out with a new human stem cell-derived model reveals that the most prevalent genetic risk factor of Alzheimer’s disease, apolipoprotein E4, impairs the function of human brain immune cells, microglia.
New facilities expand services offering to Irish and International customers
Lysando AG, market leader for antimicrobial proteins based in Liechtenstein, has established an Ethical Committee, composed of two renowned members, who will serve on a voluntary basis, Leonhard Stärk and Dr. Karl Liese.
Helsinn and Mundipharma China Pharmaceutical jointly announce that the National Medical Products Administration has approved the oral formulation of Akynzeo® for the treatment of chemotherapy-induced nausea and vomiting in China.
Horizon Discovery Group plc announces its results for the six months ended 30 June 2019.
Akari Therapeutics, Plc announced that the U.S. Food and Drug Administration has granted orphan drug designation for nomacopan for the treatment of bullous pemphigoid.
Mologic Ltd announced that it has finished recruitment to a major clinical trial with University College London Hospitals (UCLH) to evaluate the Company’s point-of-care (POC) diagnostic test for the early detection of sepsis.
PRESS RELEASES